Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors

(2022) David John Allsup et al.   AMERICAN JOURNAL OF HEMATOLOGY

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

(2022) Jan A. Burger et al.   LEUKEMIA & LYMPHOMA

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

(2022) Tait D. Shanafelt et al.   BLOOD

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia

(2021) Dena R. Howard et al.   Trials

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

(2019) Tait D. Shanafelt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

(2019) Talha Munir et al.   AMERICAN JOURNAL OF HEMATOLOGY

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

(2019) Ilaria Del Giudice et al.   Frontiers in Oncology

Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

(2018) Jan A. Burger et al.   BLOOD

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

(2018) Carol Moreno et al.   LANCET ONCOLOGY

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL

(2017) T Munir et al.   LEUKEMIA

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL

(2017) D R Howard et al.   LEUKEMIA

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial

(2011) Stefano Molica   Expert Review of Anticancer Therapy

Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression Analysis

(2010) Dirk Bassler   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Stopping clinical trials early for benefit: impact on estimation

(2009) Boris Freidlin et al.   Clinical Trials

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005

(2009) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD